Concept · Learn
Which peptide for energy? MOTS-c, NAD+ & SS-31
A peptide for energy is marketed as a way to support mitochondria, but the evidence depends on the compound. MOTS-c improves metabolic and exercise outcomes mainly in mice, SS-31 has human drug data for a rare mitochondrial disease, and NAD+ is not a peptide and has mixed human energy results.
What counts as an energy peptide?
Energy peptides are compounds grouped by a goal, not a single scientific class. MOTS-c and SS-31 are peptides connected to mitochondrial biology. NAD+ sits beside them in longevity discussions because cells use it during energy metabolism, but NAD+ is a coenzyme, not a chain of amino acids. The outcome distinction matters more: making cellular energy is not the same as feeling more energetic.
Mitochondria turn energy from food into adenosine triphosphate (ATP), the molecule cells spend to do work. A compound can change that machinery in cells, alter a blood marker, or improve a disease-specific test without reducing everyday fatigue or boosting exercise performance. Those are separate claims, and each needs its own evidence.
The useful evidence ladder is simple:
| Claim | What would support it? |
|---|---|
| Changes an energy pathway | Cell or biochemical measurements |
| Improves mitochondrial function | Tissue or physiological measurements |
| Improves exercise capacity | Controlled performance testing |
| Makes people feel more energetic | Controlled human symptom data |
Is MOTS-c the main peptide for energy?
MOTS-c is the closest match to a literal peptide for energy because it is a 16-amino-acid signal encoded in mitochondrial DNA and tied to metabolic stress responses. In mice, administered MOTS-c has improved insulin sensitivity and physical performance. Completed human studies have mostly measured the body’s own MOTS-c rather than testing injected MOTS-c as an energy treatment.
MOTS-c activates pathways that include AMP-activated protein kinase (AMPK), a sensor that responds when cellular fuel runs low. Think of AMPK as a low-fuel warning light: the signal changes how the cell handles glucose and fat. The indexed MOTS-c literature supports the mechanism and the animal findings, but those results do not establish more energy in people.
Human testing is moving forward. A Phase 2 trial in adults with prediabetes is evaluating insulin sensitivity and cardiometabolic measures after MOTS-c treatment. The trial is not a general fatigue study, and it has no posted results yet. For now, the energy claim remains animal-led rather than human-proven.
Does NAD+ increase energy?
NAD+ is essential to cellular energy metabolism, but taking NAD+ or a precursor has not reliably made healthy people feel more energetic in controlled trials. Human studies show that precursors such as nicotinamide riboside and NMN can raise NAD+ levels. The harder part—turning a higher level into better energy, performance, or function—has produced mixed results.
NAD+ works like a reusable electron shuttle. NAD+ accepts electrons while nutrients are broken down, becomes NADH, and helps deliver those electrons to processes that make ATP. That biology is settled. The supplement claim adds another step: more NAD+ must improve an outcome a person can notice. The randomized human literature on NAD+ precursors and energy does not support treating those two statements as interchangeable.
IV NAD+ belongs in a separate evidence bucket. Wellness clinics market infusions for energy and focus, but controlled evidence for those outcomes is sparse. A bag entering a vein proves delivery, not benefit. NAD+ therefore belongs in this comparison, but calling it an energy peptide is chemically wrong and clinically ahead of the results.
Is SS-31 better supported than MOTS-c?
SS-31, also called elamipretide, has more human drug development behind it than MOTS-c, but that does not make SS-31 a proven energy booster. SS-31 binds cardiolipin, a lipid in the inner mitochondrial membrane. FDA approved elamipretide as Forzinity for a narrow use in Barth syndrome, not for fatigue, athletic performance, or general mitochondrial support.
SS-31 is a synthetic four-amino-acid peptide designed to concentrate in mitochondria. The power-plant analogy works here: cardiolipin helps organize the membrane where energy machinery operates, and SS-31 is meant to stabilize that working surface. The official Forzinity prescribing information identifies elamipretide as a mitochondrial cardiolipin binder and limits the approved indication to eligible patients with Barth syndrome.
That approval is meaningful evidence for one rare mitochondrial disorder. SS-31 studies in broader mitochondrial disease, heart failure, and aging have not produced a general-purpose energy indication. Research-market SS-31 powder also does not inherit the approved product’s manufacturing controls or label.
Which option has the strongest evidence for more energy?
No option has strong human evidence for making a generally healthy person feel more energetic. MOTS-c has the most direct peptide-and-exercise narrative, but outcome evidence is mainly from mice. NAD+ precursors have randomized human data showing target engagement, with mixed functional results. SS-31 has the deepest clinical program and an FDA-approved disease use, but not an approval for everyday energy.
| Compound | What it is | Best-supported point | Missing piece for the energy claim |
|---|---|---|---|
| MOTS-c | Mitochondrial-derived peptide | Metabolic and performance effects in mice | Completed treatment trials showing human energy or performance benefits |
| NAD+ | Coenzyme, not a peptide | Precursors can raise NAD+ in humans | Consistent improvement in energy, fatigue, or physical function |
| SS-31 | Mitochondria-targeting peptide | Approved elamipretide product for Barth syndrome | Evidence for energy or performance in healthy people |
This is why mechanism-first rankings often mislead. All three touch energy biology, but the measured human outcome is the finish line. Readers can use the evidence-grading guide to separate a pathway result from a result that changes how someone feels or performs.
Are energy peptides safe?
Energy peptides do not share one safety profile. MOTS-c lacks a mature human safety record, especially for long-term use outside trials. SS-31 has clinical and label data, with injection-site reactions documented for the approved product. NAD+ precursor trials generally report tolerability, while IV NAD+ has different route-specific concerns and no FDA-approved energy indication.
Product quality adds another layer. A regulated prescription product, a dietary-supplement precursor, a compounded infusion, and a research chemical are not interchangeable merely because a longevity clinic places them on the same menu. Purity, sterility, dosing accuracy, and medical oversight differ across those categories.
The clearest read is hopeful but narrow: mitochondrial signaling is an active research field, and the first proper MOTS-c treatment trial is underway. Today, though, choosing a peptide for energy means choosing among different mechanisms and incomplete outcome data—not selecting a clinically established fix. The broader longevity and mitochondrial peptide hub keeps those evidence levels visible.